Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2023-02-17 Interim / Quarterly Rep…
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the fourth quarter and annual results 2022' and contains comprehensive financial statements (Income statement, Report on financial position, Cash flow, etc.) for the period ending Q4 2022. It provides detailed management commentary, operational updates, and financial performance metrics. It is a full interim/quarterly report, not an announcement or a summary. Q4 2022
2023-02-17 English
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for 'Nordnet AB (publ)' concerning 'SynAct Pharma AB' instruments. It explicitly shows the 'Before the transaction' and 'After the transaction' share quantities and voting rights, noting that the holder 'underskridit tröskelvärdet 5%' (crossed below the 5% threshold). This structure—tracking changes in ownership percentage against a defined threshold—is the defining characteristic of a Major Shareholding Notification. The filing type code corresponding to this is MRQ (Major Shareholding Notification). The document is a direct report of the change, not an announcement of a report's publication.
2023-02-01 English
Patrik Renblad is leaving SynAct Pharma and the search for a new CFO has been initiated
Board/Management Information Classification · 100% confidence The document explicitly announces that the Chief Financial Officer (CFO), Patrik Renblad, has resigned and will be leaving the company. This directly relates to a change in senior management. Based on the provided definitions, this aligns perfectly with the 'Board/Management Information' category.
2023-02-01 English
Patrik Renblad lämnar SynAct Pharma och rekryteringen av en ny CFO har inletts
Board/Management Information Classification · 100% confidence The document is a short announcement in Swedish stating that the CFO, Patrik Renblad, is resigning and the recruitment for a new CFO has started. This directly concerns a change in senior management. Based on the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is short and serves as an announcement, not a comprehensive report, confirming the classification as MANG.
2023-02-01 Swedish
Change in number of shares and votes in SynAct Pharma
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly details a 'Change in number of shares and votes' resulting from an 'issue in kind of shares' approved by an extraordinary general meeting. This action directly impacts the company's capital structure by increasing the total number of outstanding shares and the share capital. This aligns perfectly with the definition of 'Share Issue/Capital Change' (Code: SHA). Although it is a regulatory announcement, the specific nature of the content (share count change) makes SHA a more precise classification than the general RNS.
2023-01-31 English
Ändring av antalet aktier och röster i SynAct Pharma
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement in Swedish regarding a change in the total number of shares and votes due to a share issue (apportemission) completed in January 2023. It explicitly states the increase in shares and capital and concludes with a statement that this information is required to be made public according to financial instrument trading laws, followed by a link to an attached PDF file. Since the document itself is a brief notification announcing a corporate action (change in share count/capital) and points to a separate document, it fits the description of a general regulatory announcement or a specific capital change notification. Given the content focuses entirely on the change in the number of shares and votes resulting from a capital action, the most specific code is 'SHA' (Share Issue/Capital Change). Although it could be RNS, SHA is more precise for share count changes.
2023-01-31 Swedish

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.